46 results found.

Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adeno Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

Ovarian Cancer, Epithelial Tumors, Malignant, Fallopian Tube Canc Clinical Trial using DNIB0600A; pegylated liposomal doxorubicin

Genentech - Recruiting 18 years or older.
- A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER.
DNIB0600A; pegylated liposomal doxorubicin

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy.
laboratory biomarker analysis

Ovarian Carcinosarcoma, Recurrent Ovarian Epithelial Cancer, Recu Clinical Trial using paclitaxel; carboplatin; ifosfamide

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary.
paclitaxel; carboplatin; ifosfamide

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using behavioral dietary intervention; exercise intervention; counseling intervention; educational intervention; compliance monitoring; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?.
behavioral dietary intervention; exercise intervention; counseling intervention; educational intervention; compliance monitoring; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using elesclomol sodium; paclitaxel

Gynecologic Oncology Group - Recruiting 18 years or older.
- A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
elesclomol sodium; paclitaxel

Stage I Ovarian Epithelial Cancer, Stage I Primary Peritoneal Cav Clinical Trial using pharmacological study; questionnaire administration; assessment of therapy complications; quality-of-life assessment; carboplatin; paclitaxel; filgrastim

Gynecologic Oncology Group - Recruiting 75 years or older.
- Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer.
pharmacological study; questionnaire administration; assessment of therapy complications; quality-of-life assessment; carboplatin; paclitaxel; filgrastim

Biochemical-recurrent Only Epithelial Ovarian Cancer, Primary Per Clinical Trial using INCB024360; tamoxifen

Incyte Corporation - Recruiting 18 years or older.
- A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy.
INCB024360; tamoxifen

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Ovarian Cancer Clinical Trial using pertuzumab; placebo; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A TWO-PART, RANDOMIZED PHASE III, DOUBLE-BLIND, MULTICENTER TRIAL ASSESSING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH STANDARD CHEMOTHERAPY VS. PLACEBO PLUS STANDARD CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER AND LOW HER3 mRNA EXPRESSION.
pertuzumab; placebo; chemotherapy

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peri Clinical Trial using pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

VentiRx Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Clinical Trial using Oral rucaparib

Clovis Oncology, Inc. - Recruiting 18 years or older.
- A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2).
Oral rucaparib

Fallopian Tube Cancer, Ovarian Cancer, or Peritoneal Cancer Clinical Trial using AMG 386; Paclitaxel; AMG 386 Placebo; Carboplatin

Amgen - Recruiting 18 years or older.
- A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
AMG 386; Paclitaxel; AMG 386 Placebo; Carboplatin

Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Can Clinical Trial using Tivozanib

Northwestern University - Recruiting 18 years or older.
- The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Tivozanib

Ovarian Neoplasms, Peritoneal Neoplasms, or Fallopian Tube Neopla Clinical Trial using Trabectedin; DOXIL; Dexamethasone

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Trabectedin; DOXIL; Dexamethasone

Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, or Peri Clinical Trial using carboplatin; cisplatin; paclitaxel; quality-of-life assessment

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Phase II/III Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy.
carboplatin; cisplatin; paclitaxel; quality-of-life assessment

Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal C Clinical Trial using Birinapant; Conatumumab

TetraLogic Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer.
Birinapant; Conatumumab

Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial C Clinical Trial using IDO1 inhibitor INCB024360; therapeutic conventional surgery; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 19 years or older.
- A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.
IDO1 inhibitor INCB024360; therapeutic conventional surgery; laboratory biomarker analysis

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912).
paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Clinical Trial using veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy.
veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Clinical Trial using mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

University of Chicago - Recruiting 18 years or older.
- Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer.
mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

Epithelial Ovarian Cancer Clinical Trial using Placebo Study Agent; Cvac

Prima BioMed Ltd - Recruiting 18 years or older.
- A Randomized, Double-Blinded, Placebo-Controlled Trial of Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-Line Chemotherapy (Australia and United States) / A Randomized Trial of Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-Line Chemotherapy or Following Second-Line Treatment (EU and EEU).
Placebo Study Agent; Cvac

Peritoneal Neoplasms Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

Epithelial Ovarian Cancer Clinical Trial using CAELYX; Topotecan HCl

Xian-Janssen Pharmaceutical Ltd. - Recruiting 18 years or older.
- A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYXr Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy.
CAELYX; Topotecan HCl

Ovarian Epithelial Cancer, Carcinoma in Situ, or Ovarian Cancer Clinical Trial using Lavage of the Cavum uteri and proximal Fallopian tubes

Medical University of Vienna - Recruiting 18 years to 80 years.
- Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma.
Lavage of the Cavum uteri and proximal Fallopian tubes

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using wild-type reovirus; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN NSC # 729968, BB-IND #13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
wild-type reovirus; paclitaxel

Epithelial Ovarian Cancer Clinical Trial using Bevacizumab

ARCAGY/ GINECO GROUP - Recruiting 18 years or older.
- Non Interventional Study Dealing With the Use of Bevacizumab (Avastinr) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy.
Bevacizumab

Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Clinical Trial using Rucaparib; Placebo

Clovis Oncology, Inc. - Recruiting 18 years or older.
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3).
Rucaparib; Placebo

Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystade Clinical Trial using paclitaxel; carboplatin; bevacizumab; veliparib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I STUDY OF INTRAVENOUS CARBOPLATIN/PACLITAXEL OR INTRAVENOUS AND INTRAPERITONEAL PACLITAXEL/CISPLATIN IN COMBINATION WITH CONTINUOUS OR INTERMITTENT/ CTEP-SUPPLIED AGENT ABT-888 (NSC #737664) AND CTEP-SUPPLIED AGENT BEVACIZUMAB (NSC #704865) IN NEWLY DIAGNOSED PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
paclitaxel; carboplatin; bevacizumab; veliparib; laboratory biomarker analysis

Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Clinical Trial using TroVaxr; Placebo

University College, London - Recruiting 18 years or older.
- A Randomised Parallel Group Double-Blind Phase II Study to Assess the Activity of TroVaxr (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
TroVaxr; Placebo

Ovarian Cancer Clinical Trial

Hellenic Oncology Research Group - Recruiting 18 years or older.
- A Multicentre, Observational Study of Bevacizumab (Avastin) Added to Front-line Chemotherapy in Patients With Stage IIIb, IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma in Routine Clinical Practice..

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using paclitaxel poliglumex; clinical observation; paclitaxel

Gynecologic Oncology Group - Recruiting N/A or older.
- A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND #70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.
paclitaxel poliglumex; clinical observation; paclitaxel

Epithelial Ovarian Cancer Clinical Trial using FES-PET

University Medical Centre Groningen - Recruiting 18 years or older.
- Feasibility Study: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer.
FES-PET

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peri Clinical Trial using Acute Normovolemic Hemodilution

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 69 years.
- A Pilot Study of Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer.
Acute Normovolemic Hemodilution

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using bortezomib; carboplatin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I PHARMACOKINETIC STUDY OF INTRAPERITONEAL CTEP-SUPPLIED AGENT BORTEZOMIB (PS-341, NSC 681239, IND# 58443) AND CARBOPLATIN (NSC# 241240) IN PATIENTS WITH PERSISTENT OR RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.
bortezomib; carboplatin; pharmacological study

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With Pegylated Liposomal Doxorubicin (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using carboplatin; ifosfamide; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY.
carboplatin; ifosfamide; hyperthermia treatment

Ovarian Cancer Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin

National Cancer Institute, Naples - Recruiting 18 years or older.
- A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS.
Bevacizumab; Paclitaxel; Carboplatin

Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Canc Clinical Trial using Alvimopan; Placebo

Mayo Clinic - Recruiting 18 years or older.
- Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial.
Alvimopan; Placebo

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using carboplatin; paclitaxel; pazopanib hydrochloride; laboratory biomarker analysis; pharmacological study

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years or older.
- Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma.
carboplatin; paclitaxel; pazopanib hydrochloride; laboratory biomarker analysis; pharmacological study

Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Fa Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin; specialized pathology review (Germany only)

AGO Study Group - Recruiting 18 years or older.
- A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer.
Bevacizumab; Paclitaxel; Carboplatin; specialized pathology review (Germany only)

Ovarian Cancer Clinical Trial using Catumaxomab

Grupo Espa¤ol de Investigaci¢n en Cáncer de Ovario - Recruiting 18 years or older.
- A Phase II of Intraperitoneal Catumaxomab as a Consolidation Therapy in Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma in Second or Third Complete Clinical Disease Remission.
Catumaxomab

Epithelial Ovarian Cancer, Which is Platinum Resistant or Refract Clinical Trial using Pazopanib and Cyclophosphamid

University Hospital Heidelberg - Recruiting 18 years or older.
- A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer.
Pazopanib and Cyclophosphamid

Epithelial Ovarian Carcinoma, or Figo Stage IIIC Clinical Trial using hyper thermic chemo + surgery

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years to 65 years.
- Phase II Study of Intra-Peritoneal Hyper-Thermic Chemotherapy as Consolidation Therapy for Advanced Epithelial Ovarian Carcinoma.
hyper thermic chemo + surgery